cerca CERCA
Lunedì 23 Dicembre 2024
Aggiornato: 09:39
10 ultim'ora BREAKING NEWS

texas

comunicato stampa

GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials

PLANTATION, Florida and HOUSTON, Texas, Oct. 7, 2024 /PRNewswire/ -- GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), and Allterum Therapeutics, a Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candidate 4A10 into clinic. 4A10 is a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers. 



SEGUICI SUI SOCIAL



threads whatsapp linkedin twitter youtube facebook instagram
ora in
Prima pagina
articoli
in Evidenza